Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. Obexelimab is a non-depleting anti-human CD19 mAb with an Fc region engineered to have high affinity for human FcγRIIb, thereby co-engaging BCR and FcγRIIb. To assess...

Full description

Bibliographic Details
Main Authors: Seung Y. Chu, Erik Pong, Christine Bonzon, Ning Yu, Chaim O. Jacob, Samantha A. Chalmers, Chaim Putterman, David E. Szymkowski, William Stohl
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Journal of Translational Autoimmunity
Subjects:
B cells
FcγRIIb
Lupus
Murine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909020300423

Similar Items

Similar Items